SkyView Investment Advisors’s Estrella Immunopharma Warrant ESLAW Stock Holding History

SkyView Investment Advisors’s Portfolio ESLAW Stock Details ESLAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5K	Hold	62,500	–	–	﹤0.01%	290
2025 Q4	$5K	Hold	62,500	–	–	﹤0.01%	303
2025 Q3	$3K	Hold	62,500	–	–	﹤0.01%	299
2025 Q2	$3K	Hold	62,500	–	–	﹤0.01%	300
2025 Q1	$6K	Hold	62,500	–	–	﹤0.01%	287
2024 Q4	$4K	Hold	62,500	–	–	﹤0.01%	261
2024 Q3	$6K	Hold	62,500	–	–	﹤0.01%	265
2024 Q2	$4K	Hold	62,500	–	–	﹤0.01%	312
2024 Q1	$3K	Hold	62,500	–	–	﹤0.01%	307
2023 Q4	$2K	Hold	62,500	–	–	﹤0.01%	123
2023 Q3	$15K	Hold	62,500	–	–	0.01%	336
2023 Q2	$3K	Hold	62,500	–	–	﹤0.01%	550
2023 Q1	$6K	Hold	62,500	–	–	﹤0.01%	473
2022 Q4	$3K	Buy	+62,500	New	+$5.22K	﹤0.01%	455

Other funds holding ESLAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

SkyView Investment Advisors's ESLAW Position: Q1 2026 in Review

SkyView Investment Advisors held its Estrella Immunopharma Warrant (ESLAW) position steady in Q1 2026 at 62,500 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #290.

SkyView Investment Advisors first reported a position in ESLAW in Q4 2022 and has held it in 14 quarters since. The position peaked at $15K in Q3 2023. 8 funds tracked by Wall St. Rank hold ESLAW as of Q1 2026.

SkyView Investment Advisors held 62,500 shares of Estrella Immunopharma Warrant worth $5K as of Q1 2026.
SkyView Investment Advisors left its Estrella Immunopharma Warrant share count unchanged in Q1 2026.
Estrella Immunopharma Warrant made up ﹤0.01% of SkyView Investment Advisors's portfolio in Q1 2026, its #290 holding.
SkyView Investment Advisors first reported a position in Estrella Immunopharma Warrant in Q4 2022 and has held it in 14 quarters since.
SkyView Investment Advisors's Estrella Immunopharma Warrant position peaked at $15K in Q3 2023.
8 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q1 2026.

Based on SkyView Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.